William Blair Has Strong Estimate for KZR FY2024 Earnings

Kezar Life Sciences, Inc. (NASDAQ:KZR - Free Report) - Research analysts at William Blair lifted their FY2024 earnings per share estimates for Kezar Life Sciences in a research note issued on Wednesday, November 13th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($2.06) for the year, up from their previous estimate of ($12.50). William Blair has a "Market Perform" rating on the stock. The consensus estimate for Kezar Life Sciences' current full-year earnings is ($6.47) per share. William Blair also issued estimates for Kezar Life Sciences' Q4 2024 earnings at ($2.81) EPS, Q1 2025 earnings at ($2.73) EPS, Q2 2025 earnings at ($2.75) EPS, Q3 2025 earnings at ($2.78) EPS, Q4 2025 earnings at ($2.80) EPS, FY2025 earnings at ($11.06) EPS, FY2026 earnings at ($11.86) EPS and FY2027 earnings at ($12.84) EPS.

Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.25.

A number of other brokerages have also issued reports on KZR. HC Wainwright reissued a "neutral" rating on shares of Kezar Life Sciences in a report on Monday, October 14th. Wells Fargo & Company dropped their target price on Kezar Life Sciences from $20.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday.

Kezar Life Sciences Price Performance

KZR stock traded down $0.07 during trading on Monday, hitting $7.39. The stock had a trading volume of 59,129 shares, compared to its average volume of 73,697. The company's 50-day moving average price is $7.20 and its two-hundred day moving average price is $6.82. Kezar Life Sciences has a twelve month low of $5.20 and a twelve month high of $11.35. The stock has a market capitalization of $53.92 million, a P/E ratio of -0.56 and a beta of 0.22. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 9.58.

Institutional Trading of Kezar Life Sciences

Hedge funds have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC purchased a new stake in shares of Kezar Life Sciences in the 1st quarter valued at approximately $1,588,000. Stonepine Capital Management LLC acquired a new stake in Kezar Life Sciences in the second quarter valued at $630,000. Acadian Asset Management LLC lifted its holdings in Kezar Life Sciences by 42.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company's stock worth $1,613,000 after buying an additional 534,203 shares during the last quarter. Acuitas Investments LLC boosted its position in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company's stock worth $592,000 after acquiring an additional 295,956 shares in the last quarter. Finally, Ikarian Capital LLC boosted its position in shares of Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company's stock worth $827,000 after acquiring an additional 200,000 shares in the last quarter. Institutional investors and hedge funds own 67.90% of the company's stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.